Immunokey
Develops CAR T-cell therapies for solid cancers, starting with ovarian cancer
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-09
About Immunokey
ImmunoKey is developing a platform technology intended to expand CAR T-cell therapy to solid cancers. Its lead product targets ovarian cancer.
The company’s research focuses on developing cell therapies for patients with cancer. Its team includes leadership, scientific staff, board members and clinical and scientific advisors.
IMMUNOKEY LTD was founded in 2024 and is registered in Wilmslow, United Kingdom.
Product: A CAR T-cell therapy platform for solid cancers, with a lead product targeting ovarian cancer.
Jobs at Immunokey
More biotech & pharma companies
immunologicaltoolbox.co.uk
Online antibody repository for veterinary immunology researchers, with community ratings and reagent requestsNew on EvolcImmutrin
Develops antibody therapies to remove amyloid deposits for people with amyloidosis, including ATTR cardiomyopathyNew on EvolcIMU Biosciences
Immune profiling and precision-medicine tools for clinical research, pharmaceutical, biotech and diagnostics organizationsRemote-friendlyInfectopharm
Pharmaceutical products for healthcare providers and distribution partners in the UK marketYoung companyNew on EvolcInfinitopes
Develops off-the-shelf precision cancer vaccines for cancer patients, using tumour-specific targets and engineered viral vectorsNew on EvolcIngenza
Biotechnology CRDMO developing and manufacturing biologics, pharmaceuticals and industrial products for companiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
